Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Double Point Ventures
Deal Size : Undisclosed
Deal Type : Merger
Lumos Pharma to Go Private with Double Point Ventures At $4.25/Share
Details : Lumos’ lead therapeutic candidate, LUM-201 (ibutamoren ), is a novel, oral growth hormone (GH) secretagogue, currently being evaluated in multiple Phase 2 in Pediatric Growth Hormone Deficiency.
Brand Name : LUM-201
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 23, 2024
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Double Point Ventures
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LUM-201 (ibutamoren mesylate), an oral growth hormone stimulating small molecule which increases growth hormone levels by mimicking the action of the hormone ghrelin and binding to one of the ghrelin receptors in the brain.
Brand Name : LUM-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 05, 2023
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LUM-201 (ibutamoren mesylate), an oral growth hormone stimulating small molecule which increases growth hormone levels by mimicking the action of the hormone ghrelin and binding to one of the ghrelin receptors in the brain.
Brand Name : LUM-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 28, 2023
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LUM-201, an oral growth hormone secretagogue, has a unique mechanism of action, targeting specific receptors on the pituitary and hypothalamus to stimulate the natural pulsatile secretion of growth hormone for moderate idiopathic PGHD patients.
Brand Name : LUM-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 12, 2022
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LUM-201, an oral growth hormone stimulating small molecule demonstrate a favorable safety profile as data from both OraGrowtH trials to date show comparable safety and tolerability to the rhGH subjects in the trials.
Brand Name : LUM-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 14, 2022
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Massachusetts General Hospital
Deal Size : Undisclosed
Deal Type : Collaboration
Details : LUM-201 (ibutamoren) is an orally administered small molecule that promotes the secretion of Growth Hormone from the pituitary gland. This investigator-initiated Phase 2 trial is a single-site, 6-month, open-label pilot study of daily oral LUM-201 in adu...
Brand Name : LUM-201
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : Ibutamoren
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Massachusetts General Hospital
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lumos Pharma intends to analyze these interim datasets separately and also perform a combined analysis to increase the number of subjects in the top two LUM-201 dose cohorts.
Brand Name : LUM-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2022
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The subgroup of the Merck 020 trial specifically examined the effect LUM-201 had on the pulsatile secretion of growth hormone (GH) over 24 hours in patients with PGHD after 6 months of treatment with LUM-201, compared to that patient’s baseline GH secr...
Brand Name : LUM-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2021
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Poster 7102 presents an analysis of data from a prior clinical study comparing the peak growth hormone (GH) response of LUM-201 to that of standard GH secretagogues in children naïve-to-treatment, previously diagnosed with growth hormone deficiency (GHD...
Brand Name : LUM-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2021
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Merck 020 study was a placebo-controlled trial of LUM-201 and recombinant human growth hormone (rhGH) in which all randomized subjects had pretreatment testing, including IGF-1 and peak GH levels determined after a single dose of LUM-201.
Brand Name : LUM-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 04, 2021
Lead Product(s) : Ibutamoren
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?